SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE SCHOOL OF PHARMACY

Introduction

- Proton pump inhibitors (PPIs) and hista receptor-2 antagonists (H2RAs) are wid used by patients in both the institutional and in the community for many indication
- One such indication is reducing the risk ulcers in high risk patients, such as those taking oral corticosteroids.
- Several studies have determined PPIs inappropriately prescribed in a large nu patients.
- There is limited data on readmission ration patients who are prescribed these medi

Objective

 To determine if there is a difference in 3 readmission rates in patients on acid re therapy (PPI or H2RA) alone or in com with oral corticosteroids.


Methods

- Retrospective chart review approved by Institutional Review Board at a 500-bed teaching hospital in Springfield, Illinois
- Inclusion Criteria:
 - Adults 18 years old or older who wer discharged on a PPI or H2RA in com with a corticosteroid as well as patien discharged with a corticosteroid alon
- Data Collected:
 - Patient demographics
 - Comorbid conditions (Prior MI, CHF,
 - Discharge medications
 - Hospital admissions within last year
 - ED visits within last 6 months
- Data Analysis: Descriptive Statistics and multivariate logistic regression

Effects of Proton Pump Inhibitors vs Histamine Type-2 **Receptor Antagonists in Combination with Oral Corticosteroids on Hospital Readmission Rates** Hunter Ragan, Pharm.D. Candidate; Carrie Vogler, Pharm.D. **Robert Robinson, MD**

-			
amine dolv	1916	adult	
dely	discharges		
al setting		\mathcal{O}	
ions.		_	
k of			
ose		8	
		1	
		3	
to be			
umber of			
	16	85	
ates for	Inclu	ided	
dications.			
	1248		
	Not readmitted	Rea	
30-day	within 30 days	withi	
eduction	Table 1: Study populat	tion Baseline	
		Not readmit	
bination		days n = 1248	
	Age, mean (SD)	11 - 1240 63 (16)	
	Female (%)	208 (48%)	
	Length of stay (SD) Hospital admissions in the last year (SD)	7.74 (7.17)	
w tho	Emergency department visits in last 6 months	0.40 (1.25)	
y the	(SD)		
d	HOSPITAL Score (SD)	3.85 (1.43)	
	LACE Index (SD) Charlson Comorbidity Score (SD)	11.4 (2.44) 4.97 (3.28)	
	Medical Comorbidities (%)		
ro	Myocardial infarction	340 (27%)	
re	Congestive heart failure Peripheral artery disease	291 (23%) 114 (9%)	
nbination	Stroke	74 (6%)	
ents	Dementia	38 (3%)	
าย	Chronic lung disease Connective tissue disease	352 (28%) 28 (2%)	
	Peptic ulcer disease	59 (5%)	
	Cirrhosis	40 (3%)	
	Diabetes without complications	268 (22%)	
, etc.)	Diabetes with complications Paralysis	143 (12%) 44 (4%)	
	Renal disease	237 (19%)	
•	Cancer	89 (7%)	
	Metastatic cancer Oral Corticosteroid Therapy (%)	27 (2%) 208 (16%)	
	Gastric Acid Secretion Inhibitor (%)		
nd	Proton pump inhibitor	534 (43%)	
	H2 Receptor Antagonist	139 (11%)	
	Drug combinations (%) PPI + Oral Steroids	96 (7%)	

Results



0.048


0.249

34 (8%)

41 (9%)



stic Regression of Potential Risk Factors with 30 Day Readmissions			
Odds Ratio (95% CI)	P value		
1.32 (1.15-1.50)	< 0.001		
1.25 (1.13-1.39)	< 0.001		
1.462 (1.31-1.63)	< 0.001		
0.87 (0.80-0.94)	< 0.001		
1.51 (1.12-2.04)	0.007		
1.40 (1.03-1.90)	0.031		
0.59 (0.36-0.93)	0.035		
	Odds Ratio (95% CI) 1.32 (1.15-1.50) 1.25 (1.13-1.39) 1.462 (1.31-1.63) 0.87 (0.80-0.94) 1.51 (1.12-2.04) 1.40 (1.03-1.90)		



Discussion

Hospitalization within last year, ED visit within last 6 months, increased HOSPITAL score, CHF, and renal disease may indicate increased 30-day

• H2RA use and lower LACE index score associated with lower 30-day readmission risk

• PPI use alone was not associated with increased

Limitations include lack of standard dosing protocol and differences in baseline disease states

• Corticosteroids in combination with PPIs or H2RAs were not associated with higher 30-day readmission

Conclusion

This data shows no correlation between the use of PPIs or H2RAs alone or with concurrent oral corticosteroid use and 30-day readmission rates. Further investigation warranted before any clinical significance can be determined